WATERTOWN, Mass.--(BUSINESS WIRE)--pSivida Corp. (NASDAQ:PSDV)(ASX:PVA)(FF:PV3), a drug delivery company with the only two ophthalmic sustained delivery products approved by the FDA for treatment of back of the eye diseases, today announced financial results for its fiscal third quarter ended March 31, 2009.
